ISDA

Deposition Date 2011-04-08

Release Date 2011-05-04

Last Version Date 2023-12-20

Entry Detail

PDB ID:

2YFX

Keywords:

TRANSFERASE

Title:

Structure of L1196M Mutant Anaplastic Lymphoma Kinase in Complex with Crizotinib

Biological Source:

Source Organism:

HOMO SAPIENS (Taxon ID: 9606)

Host Organism:

SPODOPTERA FRUGIPERDA

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

1.70 Å

R-Value Free:

0.23

R-Value Work:

0.20

R-Value Observed:

0.20

Space Group:

P 21 21 21

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Molecule:TYROSINE-PROTEIN KINASE RECEPTOR
Mutations:YES
Chain IDs:A
Chain Length:327
Number of Molecules:1
Biological Source:HOMO SAPIENS

UniProt ID:Q9UM73 Pfam ID:PF07714

Ligand Molecules

VGH

Primary Citation

Design of Potent and Selective Inhibitors to Overcome Clinical Anaplastic Lymphoma Kinase Mutations Resistant to Crizotinib.

Huang, Q, Johnson, T.W, Bailey, S, Brooun, A, Bunker, K.D, Burke, B.J, Collins, M.R, Cook, A.S, Cui, J.J, Dack, K.N, Deal, J.G, Deng, Y, Dinh, D, Engstrom, L.D, He, M, Hoffman, J, Hoffman, R.L, Johnson, P.S, Kania, R.S, Lam, H, Lam, J.L, Le, P.T, Li, Q, Lingardo, L, Liu, W, Lu, M.W, Mctigue, M, Palmer, C.L, Richardson, P.F, Sach, N.W, Shen, H, Smeal, T, Smith, G.L, Stewart, A.E, Timofeevski, S, Tsaparikos, K, Wang, H, Zhu, H, Zhu, J, Zou, H.Y, Edwards, M.P.Show

J.Med.Chem. 57 1170 ? (2014)

PMID: 24432909 DOI: 10.1021/JM401805H

Abstact

Crizotinib (1), an anaplastic lymphoma kinase (ALK) receptor tyrosine kinase inhibitor approved by the U.S. Food and Drug Administration in 2011, is efficacious in ALK and ROS positive patients. Under pressure of crizotinib treatment, point mutations arise in the kinase domain of ALK, resulting in resistance and progressive disease. The successful application of both structure-based and lipophilic-efficiency-focused drug design resulted in aminopyridine 8e, which was potent across a broad panel of engineered ALK mutant cell lines and showed suitable preclinical pharmacokinetics and robust tumor growth inhibition in a crizotinib-resistant cell line (H3122-L1196M).

Legend

Protein

Chemical

Disease

Primary Citation of related structures